Insider Buying: HCW Biologics (NASDAQ:HCWB) CFO Buys $20,071.35 in Stock

HCW Biologics Inc. (NASDAQ:HCWB) CFO Rebecca Byam acquired 14,235 shares of the stock in a transaction dated Friday, May 22nd. The stock was acquired at an average price of $1.41 per share, for a total transaction of $20,071.35. Following the completion of the transaction, the chief financial officer directly owned 57,245 shares of the company’s stock, valued at approximately $80,715.45. This represents a 33.10% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

HCW Biologics Stock Down 5.3%

Shares of HCW Biologics stock opened at $1.98 on Friday. The stock’s 50-day simple moving average is $0.76 and its 200-day simple moving average is $1.15. HCW Biologics Inc. has a 52 week low of $0.25 and a 52 week high of $8.75. The company has a market capitalization of $13.33 million, a price-to-earnings ratio of -0.21 and a beta of 1.13.

HCW Biologics (NASDAQ:HCWB) last announced its quarterly earnings data on Thursday, May 14th. The company reported $0.37 EPS for the quarter, beating the consensus estimate of ($0.44) by $0.81. HCW Biologics had a negative return on equity of 486.87% and a negative net margin of 34.73%.The business had revenue of $6.54 million for the quarter, compared to the consensus estimate of $6.54 million.

Analyst Upgrades and Downgrades

HCWB has been the topic of several research analyst reports. Maxim Group boosted their price objective on HCW Biologics from $2.00 to $5.00 and gave the company a “buy” rating in a research report on Thursday. Weiss Ratings restated a “sell (e+)” rating on shares of HCW Biologics in a research report on Tuesday, April 21st. Finally, Wall Street Zen upgraded HCW Biologics to a “hold” rating in a research report on Saturday, May 23rd. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, HCW Biologics presently has an average rating of “Hold” and an average target price of $5.00.

Institutional Investors Weigh In On HCW Biologics

An institutional investor recently bought a new position in HCW Biologics stock. Armistice Capital LLC bought a new position in HCW Biologics Inc. (NASDAQ:HCWB) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 300,180 shares of the company’s stock, valued at approximately $291,000. Armistice Capital LLC owned approximately 9.15% of HCW Biologics at the end of the most recent quarter. 2.96% of the stock is currently owned by hedge funds and other institutional investors.

HCW Biologics Company Profile

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.